Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744288 · ClinicalTrials.gov registry record · Phase 1
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
A Phase 1 study of Inhibition on Platelet Aggregation, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 1
- Study location
NCT01744288 is a Phase 1 study of Inhibition on Platelet Aggregation that has completed, run by AstraZeneca. The registered enrollment target is 258 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01744288, a Phase 1 study of Inhibition on Platelet Aggregation, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
- DRUG ASA
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744288
The ClinicalTrials.gov registry entry for NCT01744288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inhibition on Platelet Aggregation appearing as the primary indexed condition, and to 3 interventions - of which Clopidogrel is the first listed.
NCT01744288 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01744288 about?
NCT01744288 is a clinical study titled "Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets". Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
What is the current status of trial NCT01744288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2012-12. Estimated completion is 2014-04.
What conditions does trial NCT01744288 study?
This clinical trial studies the following conditions: Inhibition on Platelet Aggregation.
What interventions are being tested in trial NCT01744288?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG), ASA (DRUG).
Who is sponsoring clinical trial NCT01744288?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01744288 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.